Mechanisms of Portal Vein Tumour Thrombus Formation and Development in Patients with Hepatocellular Carcinoma

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2023 Jun 23

PMID 37349905

Authors

Zhenli Li

Mingda Zhao

Xingshun Qi

Yufu Tang

Shuqun Cheng

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is one of the most common and aggressive human malignancies worldwide. Portal vein tumour thrombus (PVTT) is considered one of most fearful complications of HCC and is strongly associated with a poor prognosis. Clarification of the mechanisms underlying the formation and development of PVTT is crucial for developing novel therapeutic strategies for HCC patients. Several studies have been made to uncover that tumour microenvironment, stem cells, abnormal gene expression and non-coding RNAs deregulation are associated with PVTT in patients with HCC in the last decade. However, the exact molecular mechanisms of PVTT in patients with HCC are still largely unknown. In the present review, we briefly summarized the molecular mechanisms underlying the formation and development of PVTT in HCC.

Citing Articles

Development and validation of a combined radiomic and clinical model based on contrast-enhanced ultrasound for preoperative prediction of CK19-positive hepatocellular carcinoma.

Liang L, Pang J, Gao R, Que Q, Wu Y, Peng J Abdom Radiol (NY). 2025; .

PMID: 39907719 DOI: 10.1007/s00261-025-04799-x.

Development and verification of a nomogram for predicting portal vein tumor thrombosis in hepatocellular carcinoma.

Liu G, Long J, Liu C, Chen J Am J Transl Res. 2025; 16(12):7511-7520.

PMID: 39822560 PMC: 11733390. DOI: 10.62347/PLQF5135.

Efficacy and safety of atezolizumab-bevacizumab vs pembrolizumab-lenvatinib in unresectable hepatocellular carcinoma: a retrospective, cohort study.

Hu Z, Yang Z, Fu Z, Fu Y, Ma Z, Zhou Z Front Immunol. 2024; 15:1472870.

PMID: 39628474 PMC: 11611749. DOI: 10.3389/fimmu.2024.1472870.

The Molecular Mechanisms of Portal Vein Thrombosis in Hepatocellular Carcinoma.

Galasso L, Cerrito L, Termite F, Mignini I, Esposto G, Borriello R Cancers (Basel). 2024; 16(19).

PMID: 39409869 PMC: 11482560. DOI: 10.3390/cancers16193247.

Liver transplantation following two conversions in a patient with huge hepatocellular carcinoma and portal vein invasion: A case report.

Liang L, Huang W, Guo Z, You H, Guo Y, Cai M World J Gastroenterol. 2024; 30(36):4071-4077.

PMID: 39351247 PMC: 11439119. DOI: 10.3748/wjg.v30.i36.4071.

References

Chen J, Wang Q, Chen X, Huang X, Liang L, Lei J . Clinicopathologic characteristics and surgical outcomes of hepatocellular carcinoma with portal vein tumor thrombosis. J Surg Res. 2011; 175(2):243-50. DOI: 10.1016/j.jss.2011.03.072. View

Villa E, Moles A, Ferretti I, Buttafoco P, Grottola A, Del Buono M . Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. Hepatology. 2000; 32(2):233-8. DOI: 10.1053/jhep.2000.9603. View

Kai A, Chan L, Lo R, Lee J, Chak-Lui Wong C, Wong J . Down-regulation of TIMP2 by HIF-1α/miR-210/HIF-3α regulatory feedback circuit enhances cancer metastasis in hepatocellular carcinoma. Hepatology. 2016; 64(2):473-87. PMC: 5074303. DOI: 10.1002/hep.28577. View

Kuzuya T, Ishigami M, Ito T, Ishizu Y, Honda T, Ishikawa T . Sorafenib . Lenvatinib as First-line Therapy for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. Anticancer Res. 2020; 40(4):2283-2290. DOI: 10.21873/anticanres.14193. View

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Bui-Nguyen T, Pakala S, Sirigiri R, Xia W, Hung M, Sarin S . NF-kappaB signaling mediates the induction of MTA1 by hepatitis B virus transactivator protein HBx. Oncogene. 2009; 29(8):1179-89. PMC: 3621706. DOI: 10.1038/onc.2009.404. View

Tang Y, Liu S, Li N, Guo W, Shi J, Yu H . 14-3-3ζ promotes hepatocellular carcinoma venous metastasis by modulating hypoxia-inducible factor-1α. Oncotarget. 2016; 7(13):15854-67. PMC: 4941282. DOI: 10.18632/oncotarget.7493. View

Li N, Guo W, Shi J, Xue J, Hu H, Xie D . Expression of the chemokine receptor CXCR4 in human hepatocellular carcinoma and its role in portal vein tumor thrombus. J Exp Clin Cancer Res. 2010; 29:156. PMC: 3002328. DOI: 10.1186/1756-9966-29-156. View

Zhu H, Wang D, Yuan T, Yan F, Zeng C, Dai X . Multikinase Inhibitor CT-707 Targets Liver Cancer by Interrupting the Hypoxia-Activated IGF-1R-YAP Axis. Cancer Res. 2018; 78(14):3995-4006. DOI: 10.1158/0008-5472.CAN-17-1548. View

10.

Khan A, Wei X, Xu X . Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides. J Hepatocell Carcinoma. 2021; 8:1089-1115. PMC: 8434852. DOI: 10.2147/JHC.S318070. View

11.

Xu X, Wei X, Ling Q, Cheng J, Zhou B, Xie H . Identification of two portal vein tumor thrombosis associated proteins in hepatocellular carcinoma: protein disulfide-isomerase A6 and apolipoprotein A-I. J Gastroenterol Hepatol. 2011; 26(12):1787-94. DOI: 10.1111/j.1440-1746.2011.06796.x. View

12.

Liu K, Duan J, Liu H, Yang X, Yang J, Wu M . Precancer antiviral treatment reduces microvascular invasion of early-stage Hepatitis B-related hepatocellular carcinoma. Sci Rep. 2019; 9(1):2220. PMC: 6379412. DOI: 10.1038/s41598-019-39440-7. View

13.

Cheng A, Kang Y, Chen Z, Tsao C, Qin S, Kim J . Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2008; 10(1):25-34. DOI: 10.1016/S1470-2045(08)70285-7. View

14.

Guo Y, Xiao Z, Yang L, Gao Y, Zhu Q, Hu L . Hypoxia‑inducible factors in hepatocellular carcinoma (Review). Oncol Rep. 2019; 43(1):3-15. PMC: 6908932. DOI: 10.3892/or.2019.7397. View

15.

Deng Z, Wang J, Xu B, Jin Z, Wu G, Zeng J . Mining TCGA Database for Tumor Microenvironment-Related Genes of Prognostic Value in Hepatocellular Carcinoma. Biomed Res Int. 2019; 2019:2408348. PMC: 6885833. DOI: 10.1155/2019/2408348. View

16.

Yang P, Li Q, Feng Y, Zhang Y, Markowitz G, Ning S . TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. Cancer Cell. 2012; 22(3):291-303. PMC: 3443566. DOI: 10.1016/j.ccr.2012.07.023. View

17.

Chai Z, Zhang X, Ao J, Zhu X, Wu M, Lau W . AXL Overexpression in Tumor-Derived Endothelial Cells Promotes Vessel Metastasis in Patients With Hepatocellular Carcinoma. Front Oncol. 2021; 11:650963. PMC: 8191462. DOI: 10.3389/fonc.2021.650963. View

18.

. Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Ann Surg. 1990; 211(3):277-87. PMC: 1358432. View

19.

Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang H . EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 2009; 136(3):1012-24. PMC: 2828822. DOI: 10.1053/j.gastro.2008.12.004. View

20.

Guo W, Liu S, Cheng Y, Lu L, Shi J, Xu G . ICAM-1-Related Noncoding RNA in Cancer Stem Cells Maintains ICAM-1 Expression in Hepatocellular Carcinoma. Clin Cancer Res. 2015; 22(8):2041-50. DOI: 10.1158/1078-0432.CCR-14-3106. View